Targeted Nasal Vaccination Provides Antibody-Independent Protection Against Staphylococcus aureus

Despite showing promise in preclinical models, anti-Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test whether a cellula...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 209; no. 9; pp. 1479 - 1484
Main Authors Misstear, Karen, McNeela, Edel A., Murphy, Alison G., Geoghegan, Joan A., O'Keeffe, Kate M., Fox, John, Chan, Kin, Heuking, Simon, Collin, Nicolas, Foster, Timothy J., McLoughlin, Rachel M., Lavelle, Ed C.
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.05.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Despite showing promise in preclinical models, anti-Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test whether a cellular-only response can protect against infection. We demonstrate that nasal vaccination with targeted nanoparticles loaded with Staphylococcus aureus antigen protects against acute systemic S. aureus infection in the absence of any antigen-specific antibodies. These findings can help inform future developments in staphylococcal vaccine development and studies into the requirements for protective immunity against S. aureus.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
R. M. M. and E. C. L. contributed equally to this work.
K. M., E. A. M., and A. G. M. contributed equally to this work.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jit636